Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 2/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | CCKBR | P32239 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12977149 | 0.86 | KDM4E (0.55) | KDM4EATML3MBTL1FGFR1PTPN1 | |
| SCHEMBL10299341 | 0.83 | PIM1 (0.46) | KDM4EFGFR1 | |
| SCHEMBL10047610 | 0.83 | PTPN1 (0.54) | KDM4EATML3MBTL1FGFR1PTPN1 | |
| SCHEMBL14454763 | 0.81 | KDM4E (0.55) | KDM4EATML3MBTL1FGFR1 | |
| SCHEMBL16890333 | 0.79 | KDM4E (0.57) | KDM4EATML3MBTL1FGFR1PPARG | |
| SCHEMBL19003188 | 0.78 | KDM4E (0.44) | KDM4EATML3MBTL1FGFR1PTPN1 | |
| SCHEMBL57391 | 0.78 | L3MBTL1 (0.73) | KDM4EATML3MBTL1 | |
| SCHEMBL29351958 | 0.78 | L3MBTL1 (0.73) | KDM4EATML3MBTL1 | |
| SCHEMBL29371952 | 0.78 | L3MBTL1 (0.73) | KDM4EATML3MBTL1 | |
| SCHEMBL28477376 | 0.77 | KDM4E (0.61) | KDM4EATML3MBTL1FGFR1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2937355-B1 | PHOSPHORUS COMPOUND AND TRANSITION METAL COMPLEX OF THE SAME | TAKASAGO PERFUMERY CO LTD (JP) | 2017-06-28 | — | — | EP | disclosed |
| US-9416148-B2 | Phosphorus compound and transition metal complex of the same | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2016-08-16 | — | — | US | disclosed |
| US-9416148-B2 | Phosphorus compound and transition metal complex of the same | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2016-08-16 | — | — | US | disclosed |
| US-20150307531-A1 | PHOSPHORUS COMPOUND AND TRANSITION METAL COMPLEX OF THE SAME | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2015-10-29 | — | — | US | disclosed |
| US-20150307531-A1 | PHOSPHORUS COMPOUND AND TRANSITION METAL COMPLEX OF THE SAME | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2015-10-29 | — | — | US | disclosed |
| EP-2937355-A1 | PHOSPHORUS COMPOUND AND TRANSITION METAL COMPLEX OF THE SAME | Takasago International Corporation (JP) | 2015-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307531-A1 | PHOSPHORUS COMPOUND AND TRANSITION METAL COMPLEX OF THE SAME | P2RY10, PTH1R, INPP5A | KDM4E 3631/4885ATM 2549/4885L3MBTL1 3743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.